Amarin 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Ligand Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sirukumab, an antibody targeting IL6.

Emergent BioSolutions 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bifikafusp, an antibody targeting FN extracellular domain B.

Mallinckrodt 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Endo 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Bausch + Lomb 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Bausch Health 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Axatilimab, an antibody targeting CSF1R.

Ichnos Sciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Apitegromab, an antibody targeting pro-MSTN.